BLAINJECTIONINJECTABLE
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NYVEPRIA (pegfilgrastim-apgf) by Pfizer is colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation. First approved in 2020.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NYVEPRIA (pegfilgrastim-apgf) is a biosimilar to Neulasta, a pegylated granulocyte colony-stimulating factor (G-CSF) that stimulates bone marrow production of neutrophils. It is indicated to reduce the incidence of chemotherapy-induced febrile neutropenia in patients receiving myelosuppressive cancer therapies. The drug works by binding to G-CSF receptors on hematopoietic cells, promoting proliferation and differentiation of neutrophil precursors.
$0.004BPart D
PeakProduct is in peak commercial phase with modest Part D penetration; biosimilar portfolio expansion suggests stable but competitive market positioning for Pfizer.
Mechanism of Action
colony-stimulating factors that act on hematopoietic cells by binding to specific cell surface receptors, thereby stimulating proliferation, differentiation, commitment, and end cell functional activation.
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on NYVEPRIA positions you in a mature biosimilar franchise where commercial acumen, payer negotiation, and competitive pricing strategy are core competencies. Career growth depends on driving market share gains in a crowded segment and supporting Pfizer's broader biosimilar portfolio rather than pioneering novel science.
Brand Manager
Worked on NYVEPRIA at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.